Skip to main content

Table 3 1-Year Outcomes in HF Population Stratified by LVEF

From: Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China

  HFrEF (n = 211) HFmrEF (n = 201) HFpEF (n = 343) p value Univariate analysis  
HFmrEF vs HFrEF HFmrEF vs HFpEF
HR/OR (95% CI) p value HR/OR (95% CI) p value
All-cause Mortality 26 (12.3%) 11 (5.5%) 16 (4.7%) 0.002 0.461 (0.227–0.935) 0.032 1.233 (0.572–2.660) 0.593
Cardiovascular Mortality 22 (10.4%) 6 (3.0%) 6 (1.7%) < 0.001 0.298 (0.120–0.737) 0.009 1.782 (0.574–5.533) 0.317
MACE 26 (12.3%) 13 (6.5%) 10 (2.9%) < 0.001 0.492 (0.245–0.987) 0.046 2.303 (0.991–5.353) 0.053
Hospitalization due to HF 40 (19.0%) 35 (17.4%) 62 (18.1%) 0.92 0.901 (0.546–1.488) 0.685 0.956 (0.605–1.509) 0.845
  1. Abbreviations: HFrEF heart failure with reduced ejection fraction, HFmrEF heart failure with mid-range ejection fraction, HFpEF heart failure with preserved ejection fraction, MACE major adverse cardiac events
  2. Statistically significant variables were highlighted in bold